Silvercrest Asset Management Group LLC Zymeworks Inc. Transaction History

Silvercrest Asset Management Group LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$4.82 - $7.7 $1.07 Million - $1.71 Million	-222,627 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $12,552 - $35,522	2,092 Added 0.95%	222,627 $1.46 Million
Q4 2021 Feb 14, 2022	BUY	$15.19 - $29.33 $1.74 Million - $3.36 Million	114,709 Added 108.39%	220,535 $3.62 Million
Q3 2021 Nov 15, 2021	SELL	$27.35 - $37.28 $66,378 - $90,478	-2,427 Reduced 2.24%	105,826 $3.07 Million
Q2 2021 Aug 16, 2021	SELL	$26.5 - $38.23 $8,374 - $12,080	-316 Reduced 0.29%	108,253 $3.76 Million
Q1 2021 May 17, 2021	BUY	$29.83 - $56.81 $794,999 - $1.51 Million	26,651 Added 32.53%	108,569 $3.43 Million
Q4 2020 Feb 16, 2021	BUY	$39.12 - $54.99 $3.2 Million - $4.5 Million	81,918 New	81,918 $3.87 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $882M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.